KR890003761A - 치료학적 아시클릭 뉴클레오시드 - Google Patents

치료학적 아시클릭 뉴클레오시드 Download PDF

Info

Publication number
KR890003761A
KR890003761A KR1019880010298A KR880010298A KR890003761A KR 890003761 A KR890003761 A KR 890003761A KR 1019880010298 A KR1019880010298 A KR 1019880010298A KR 880010298 A KR880010298 A KR 880010298A KR 890003761 A KR890003761 A KR 890003761A
Authority
KR
South Korea
Prior art keywords
compound
formula
group
salt
pharmaceutically acceptable
Prior art date
Application number
KR1019880010298A
Other languages
English (en)
Other versions
KR960002849B1 (ko
Inventor
안토니 크레니트스키 토마스
마리 비이쳄프 리리아
Original Assignee
엠.피.잭슨
더 웰컴 파운데이숀 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26292613&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR890003761(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB878719367A external-priority patent/GB8719367D0/en
Priority claimed from GB878725939A external-priority patent/GB8725939D0/en
Application filed by 엠.피.잭슨, 더 웰컴 파운데이숀 리미티드 filed Critical 엠.피.잭슨
Publication of KR890003761A publication Critical patent/KR890003761A/ko
Priority to KR1019960000775A priority Critical patent/KR960004940B1/ko
Application granted granted Critical
Publication of KR960002849B1 publication Critical patent/KR960002849B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

내용 없음

Description

치료학적 아시클릭 뉴클레오시드
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (10)

  1. 하기식(Ⅰ)의 화합물 또는 그것의 약학적 허용염.
    (이때 R1은 식 -CH(CH3)2또는 -CH(CH3)CH2CH2의 기를 나타냄)
  2. 2-(2-아미노-1,6-디하이드로-6-옥소-9H-(푸린-9-일)메톡시)에틸L-발리네이트.
  3. 2-(2-아미노-1,6-디하이드로-6-옥소-9H-(푸린-9-일)메톡시)에틸L-이소발리네이트.
  4. 제1항 내지 제3항중 어느 한항에 있어서, 그 염이 산부가염인 식(Ⅰ)화합물의 염.
  5. 제1항 내지 제4항중 어느 한항에 있어서, 그 염이 염산인 식(Ⅰ)화합물의 염.
  6. 제1항에 있어서, 의학적 용도를 위한 화합물.
  7. 제6항에 있어서, 비루스 감염의 치료 또는 예방을 위한 화합물.
  8. 제7항에 있어서, 헤르페스 심플렉스 비루스(Ⅰ)감염의 치료 또는 예방을 위한 화합물.
  9. 식(Ⅰ)의 화합물(제1항의 정의와 같음) 또는 그것의 약학적 허용염의 제조에 있어서, a) 식(Ⅱ)화합물을 임의로 보호된 발린 또는 그것의 기능적인 등가물과 반응시키거나,
    (이때 X는 임의로 보호된 수산기, Y는 임의로 보호된 아미노기임)
    b) 식(Ⅲ)화합물을 식(Ⅰ)화합물 또는 그것의 약학적 허용염으로 전화시키거나
    (이때 R1은 상기와 가고 M은 수산기, G는 아미노기로 치환될 수 있거나 또는 전환될 수 있는 원자 또는 기, 또는 G가 아미노기이며 M은 수산기로 치환되거나 또는 전환될 수 있는 원자 또는 기임)
    c)식(Ⅳ)화합물을 식(Ⅴ)화합물과 반응시킨후
    (상기식에서 X,Y와 R1은 상기와 같고 O와 A는 이탈기 또는 원자 R2는 임의로 보호된 아미노기임)
    i) 보호기 제거 ii) 식(Ⅰ)화합물이 생성되었을때, 이것을 약학적 허용 염으로 전환, iii) 약학적 허용염이 생성되었을때 이것을 모체화합물로 전환시키는 전환 공중들중 하나 이상의 공정을 필요한 순서대로 실시함을 특징으로 하는 방법.
  10. 식(Ⅰ)의 화합물의 활성성분과 그것의 약학적 허용염과 약학적 허용 담체를 함유하는 약학 조성물.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019880010298A 1987-08-15 1988-08-12 아사이클로비르의 발린 에스테르 및 이를 함유하는 약학 조성물 KR960002849B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1019960000775A KR960004940B1 (ko) 1987-08-15 1996-01-17 아사이클로비르의 이소로이신 에스테르 및 이를 함유하는 약학 조성물

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB878719367A GB8719367D0 (en) 1987-08-15 1987-08-15 Therapeutic compounds
GB8719367 1987-08-15
GB8725939 1987-11-05
GB878725939A GB8725939D0 (en) 1987-11-05 1987-11-05 Therapeutic compounds

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1019960000775A Division KR960004940B1 (ko) 1987-08-15 1996-01-17 아사이클로비르의 이소로이신 에스테르 및 이를 함유하는 약학 조성물

Publications (2)

Publication Number Publication Date
KR890003761A true KR890003761A (ko) 1989-04-17
KR960002849B1 KR960002849B1 (ko) 1996-02-27

Family

ID=26292613

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1019880010298A KR960002849B1 (ko) 1987-08-15 1988-08-12 아사이클로비르의 발린 에스테르 및 이를 함유하는 약학 조성물
KR1019960000775A KR960004940B1 (ko) 1987-08-15 1996-01-17 아사이클로비르의 이소로이신 에스테르 및 이를 함유하는 약학 조성물

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1019960000775A KR960004940B1 (ko) 1987-08-15 1996-01-17 아사이클로비르의 이소로이신 에스테르 및 이를 함유하는 약학 조성물

Country Status (30)

Country Link
EP (2) EP0596542B1 (ko)
JP (2) JPH0662623B2 (ko)
KR (2) KR960002849B1 (ko)
CN (1) CN1033701C (ko)
AP (2) AP55A (ko)
AT (1) ATE138660T1 (ko)
AU (1) AU612393C (ko)
CS (1) CS276903B6 (ko)
CY (1) CY1833A (ko)
DE (1) DE3855333T2 (ko)
DK (2) DK170045B1 (ko)
ES (1) ES2087639T3 (ko)
FI (1) FI89713C (ko)
GR (1) GR3020372T3 (ko)
HU (1) HU201071B (ko)
IE (1) IE65551B1 (ko)
IL (1) IL87434A (ko)
LU (1) LU88746I2 (ko)
LV (1) LV5264A3 (ko)
MC (1) MC1968A1 (ko)
MX (1) MX9203418A (ko)
MY (1) MY103760A (ko)
NL (1) NL960001I2 (ko)
NO (2) NO167805C (ko)
NZ (1) NZ225809A (ko)
PL (1) PL158285B1 (ko)
PT (1) PT88261B (ko)
SA (1) SA95160244B1 (ko)
SG (1) SG26346G (ko)
SU (1) SU1634138A3 (ko)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP55A (en) * 1987-08-15 1989-09-26 The Wellcome Foundation Ltd Therapeutic Acyclic Nucleosides
GB8816760D0 (en) * 1988-07-14 1988-08-17 Wellcome Found Therapeutic compounds
DE10299039I1 (de) * 1988-12-19 2003-02-20 Wellcome Found Antivirale Pyrimidin- und Purinverbindungen Verfahren zu ihrer Herstellung und sie enthaltende pharmazeutische Praeparte
GB8829571D0 (en) * 1988-12-19 1989-02-08 Wellcome Found Antiviral compounds
DE4008858A1 (de) * 1990-03-20 1991-09-26 Hoechst Ag Substituierte purine, verfahren zu ihrer hertellung sowie ihre verwendung als antivirale mittel
AU6854694A (en) * 1993-06-10 1995-01-03 Farmhispania Sa Amino acid ester of nucleoside analogues
GB9317146D0 (en) * 1993-08-18 1993-10-06 Wellcome Found Therapeutic combinations
GB9320316D0 (en) * 1993-10-01 1993-11-17 Smithkline Beecham Plc Pharmaceuticals
TW282470B (ko) * 1993-11-18 1996-08-01 Ajinomoto Kk
EP0665229B1 (en) * 1994-02-01 1999-11-17 Ajinomoto Co., Inc. Process for the production of nucleic acid base derivatives
PE32296A1 (es) * 1994-07-28 1996-08-07 Hoffmann La Roche Ester de l-monovalina derivado de 2-(2-amino-1,6-dihidro-6-oxo-purin-9-il) metoxi-1,3-propandiol y sus sales farmaceuticamente aceptables
US5543414A (en) * 1994-07-28 1996-08-06 Syntex (Usa) Inc. Achiral amino acid acyl esters of ganciclovir and its derivatives
US6083953A (en) * 1994-07-28 2000-07-04 Syntex (U.S.A.) Inc. 2- (2-amino-1,6-dihydro-6-oxo-purin-9-yl) methoxy-1,3- propanediol derivative
GB9501178D0 (en) * 1995-01-20 1995-03-08 Wellcome Found Guanine derivative
GB9501127D0 (en) * 1995-01-20 1995-03-08 Wellcome Found Tablet
GB9501142D0 (en) * 1995-01-20 1995-03-08 Wellcome Found Compounds for use in medicine
DE19536164A1 (de) * 1995-09-28 1997-04-03 Boehringer Ingelheim Kg Verbessertes Verfahren zur Herstellung von 9-[(2-Hyroxyethoxy)methyl]guanin (Acyclovir)
EP0874631B1 (en) * 1996-01-19 2003-11-19 Glaxo Group Limited Use of valaciclovir for the manufacture of a medicament for the treatment of genital herpes by a single daily application
US5840890A (en) * 1996-01-26 1998-11-24 Syntex (U.S.A.) Inc. Process for preparing a 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl)methoxy-1,3-propanediol derivative
US6040446A (en) 1996-01-26 2000-03-21 Syntex (U.S.A.) Inc. Process for preparing a 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl) methoxy-1,3-propanediol derivative
US5700936A (en) * 1996-01-26 1997-12-23 Syntex (U.S.A.) Inc. Process for preparing a 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl) methoxy-1,3-propanediol valinate
US5756736A (en) * 1996-01-26 1998-05-26 Syntex (U.S.A.) Inc. Process for preparing a 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl)methoxy-1,3-propanediol derivative
AU1543797A (en) * 1996-01-26 1997-08-20 F. Hoffmann-La Roche Ag Process for preparing purine derivatives
US5869493A (en) 1996-02-16 1999-02-09 Medivir Ab Acyclic nucleoside derivatives
US6703394B2 (en) 1996-02-16 2004-03-09 Medivir Ab Acyclic nucleoside derivatives
IT1283447B1 (it) * 1996-07-18 1998-04-21 Ind Chimica Srl Processo di preparazione del valaciclovir e relativi intermedi
CA2278474A1 (en) * 1997-01-17 1998-07-23 Ajinomoto Co., Inc. Novel z-valacyclovir crystals
EP1093364A1 (en) * 1998-05-21 2001-04-25 Magainin Pharmaceuticals Inc. A method for stimulation of defensin production by exposure to isoleucin
MXPA04002192A (es) * 2001-09-07 2005-02-17 Teva Pharma Formas cristalinas de clorhidrato de valaciclovir.
US20060147519A1 (en) 2002-06-24 2006-07-06 Ashish Gogia Process for the preparation of robust formulations of valacyclovir hydrochloride tablets
US20050043329A1 (en) * 2002-09-06 2005-02-24 Shlomit Wizel Crystalline forms of valacyclovir hydrochloride
CN1309732C (zh) * 2002-10-28 2007-04-11 南京长澳医药科技有限公司 6－烷氧基－2’，3’－双脱氧鸟嘌呤核苷的制备方法
US20050085491A1 (en) * 2003-06-02 2005-04-21 Igor Lifshitz Novel crystalline forms of valacyclovir hydrochloride
CN1331471C (zh) * 2003-09-22 2007-08-15 陈云芳 盐酸万乃洛韦软胶囊组合物
JP2007522130A (ja) * 2004-01-21 2007-08-09 テバ ファーマシューティカル インダストリーズ リミティド 塩酸バラシクロビルの調製方法
GB2413017A (en) * 2004-04-06 2005-10-12 Ford Global Tech Llc An electrical connector for a vehicle
WO2006035452A1 (en) * 2004-09-27 2006-04-06 Matrix Laboratories Ltd Novel pseudomorph of valaciclovir hydrochloride
EP1891071B1 (en) 2005-05-25 2012-02-22 Eli Lilly And Company Cyclopropanecarboxylate esters of acyclovir
EP1746098A1 (en) 2005-07-21 2007-01-24 SOLMAG S.p.A. Valacyclovir polymorphs and a process for the preparation thereof
CN101456859B (zh) * 2009-01-06 2011-07-20 华南理工大学 抗病毒药物缬昔洛韦的制备方法
WO2011158252A1 (en) 2010-06-15 2011-12-22 Matrix Laboratories Ltd Process for the preparation of valacyclovir hydrochloride polymorphic form ii
CN102850354B (zh) * 2012-10-10 2014-07-23 山东金城医药化工股份有限公司 高纯度cbz-万乃洛韦的制备方法
CN106632335A (zh) * 2016-12-27 2017-05-10 河南康达制药有限公司 一种盐酸伐昔洛韦的制备方法
RU2750867C1 (ru) * 2020-05-18 2021-07-05 Александр Сергеевич Самойлов Производные гуанина

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL8202626A (nl) * 1982-06-29 1984-01-16 Stichting Rega V Z W Derivaten van 9-(2-hydroxyethoxymethyl)guanine.
DE3627024A1 (de) * 1985-09-24 1987-04-02 Hoechst Ag In 6- und 9-stellung substituierte 2-aminopurine, ihre verwendung, diese purine enthaltende arzneimittel und verfahren zur herstellung der purine
DE3534774A1 (de) * 1985-09-30 1987-04-02 Robugen Gmbh Nucleosid-analoge verbindungen mit antiviraler aktivitaet, verfahren zu deren herstellung sowie arzneimittel mit antiviraler wirkung
AP55A (en) * 1987-08-15 1989-09-26 The Wellcome Foundation Ltd Therapeutic Acyclic Nucleosides

Also Published As

Publication number Publication date
CN1032538A (zh) 1989-04-26
NO883612D0 (no) 1988-08-12
JPH03115284A (ja) 1991-05-16
DK451388D0 (da) 1988-08-12
NO883612L (no) 1989-02-16
AP160A (en) 1991-11-18
DE3855333T2 (de) 1996-12-05
NZ225809A (en) 1991-07-26
FI89713B (fi) 1993-07-30
DK82694A (da) 1994-07-08
PL158285B1 (en) 1992-08-31
NO167805B (no) 1991-09-02
SU1634138A3 (ru) 1991-03-07
FI883757A (fi) 1989-02-16
EP0596542B1 (en) 1996-05-29
EP0308065A2 (en) 1989-03-22
AU612393B2 (en) 1991-07-11
HU201071B (en) 1990-09-28
ES2087639T3 (es) 1996-07-16
DK170803B1 (da) 1996-01-22
FI883757A0 (fi) 1988-08-12
NL960001I1 (nl) 1996-03-01
AU612393C (en) 2006-08-17
EP0308065A3 (en) 1989-09-27
EP0308065B1 (en) 1995-01-04
IL87434A0 (en) 1989-01-31
SG26346G (en) 1995-09-01
JPH0662623B2 (ja) 1994-08-17
FI89713C (fi) 1993-11-10
CS276903B6 (en) 1992-09-16
MX9203418A (es) 1992-07-01
CN1033701C (zh) 1997-01-01
LV5264A3 (lv) 1993-10-10
NO167805C (no) 1991-12-11
KR960002849B1 (ko) 1996-02-27
CS8805594A2 (en) 1990-06-13
KR960004940B1 (ko) 1996-04-18
LU88746I2 (fr) 1996-10-04
PT88261B (pt) 1995-03-01
NL960001I2 (nl) 1996-11-01
NO1996015I1 (no) 1996-12-17
DE3855333D1 (de) 1996-07-04
PT88261A (pt) 1989-06-30
CY1833A (en) 1995-12-01
AP8800099A0 (en) 1988-08-01
AP55A (en) 1989-09-26
IE882463L (en) 1989-02-15
IL87434A (en) 1993-06-10
IE65551B1 (en) 1995-11-01
JPH07113025B2 (ja) 1995-12-06
DK451388A (da) 1989-02-16
MY103760A (en) 1993-09-30
MC1968A1 (fr) 1989-09-29
HUT47935A (en) 1989-04-28
DK170045B1 (da) 1995-05-08
EP0596542A1 (en) 1994-05-11
AU2097888A (en) 1989-02-16
GR3020372T3 (en) 1996-09-30
SA95160244B1 (ar) 2006-10-02
PL274215A1 (en) 1990-02-19
JPS6468373A (en) 1989-03-14
ATE138660T1 (de) 1996-06-15

Similar Documents

Publication Publication Date Title
KR890003761A (ko) 치료학적 아시클릭 뉴클레오시드
KR900701817A (ko) 뉴클레오사이드 유도체와 그의 제조방법
KR910006293A (ko) 항비루스성 화합물, 이의 제법 및 이를 함유하는 약학적 조성물
EP0786458A3 (en) Derivatives and analogues of 2-deoxy-2,3-didehydro-n-acetyl neuraminic acid and their use as antiviral agents
KR880013967A (ko) 항비루스 화합물
IL86040A0 (en) Acid stable dideoxynucleosides,their preparation and pharmaceutical compositions containing them
DK0707481T3 (da) L-2',3'-Dideoxy-nucleosidanaloge som anti-hepatitis B (HBV)- og anti-HIV-midler
FI832355L (fi) 9-(2-hydroxyetoximetyl)guanidin-derivat
KR880012630A (ko) 치료적 뉴클레오시드
KR910009712A (ko) 세펨 화합물 및 이의 제조방법
ATE74603T1 (de) Derivate von purin, verfahren zu ihrer herstellung und pharmazeutische zubereitung.
GR3017128T3 (en) Treatment of hiv infections and compounds useful therein.
CA2002834A1 (en) Cycloalkyl xanthines
KR880012628A (ko) 치료학적인 뉴클레오시드
KR910007655A (ko) 치료용 뉴클레오시드
HUP0100087A1 (hu) Antivirális nukleozid analógok, alkalmazásuk a hepatitis B vírus és retrovirális fertőzések elleni gyógyszerkészítmények előállítására és a gyógyszerkészítmények
EP0088385A3 (en) 7-acylamino-3-cephem-4-carboxylic acid derivatives, processes for the preparation of the same and pharmaceutical composition comprising the same
KR880013927A (ko) 피리미딘 유도체
KR900001697A (ko) 치료용 화합물
KR890016059A (ko) 포스포노알킬퓨린 유도체
AU643987B2 (en) Chiral 2-(phosphonomethoxy)propyl guanines as antiviral agents
KR890012652A (ko) 소화성 궤양 질환을 치료하기 위한 치료학적 제제
KR910000728A (ko) 시클로펜탄 유도체
KR940005612A (ko) 벤조디아제핀
KR910000710A (ko) 멸균제 누클레오시드류

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20100113

Year of fee payment: 15

EXPY Expiration of term